Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteiTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Synthetic molecules may offer a way to pursue small RNAs that are difficult to target with conventional drug-discovery approaches. The phrase “undruggable” describes a design challenge, not proof that an RNA cannot be targeted—and the 2014 headline does not establish an approved medicine or a treatment for cancer.
What the 2014 headline establishes—and what it does not
The Chemistry World archive lists a research item dated 12 February 2014. Its summary describes chemists turning the drug-discovery process “on its head” to create small molecules that could potentially treat diseases such as cancer. That is an editorial summary of possible application, not evidence that a treatment was developed or tested in patients.
The available archive entry does not identify the RNA target, the synthetic strategy, the molecules produced, or the experiments behind the headline. Those details therefore cannot be attributed to this report on the evidence available here.
Why small RNAs pose a drug-discovery challenge
RNA is not a rigid, uniform target. It can be flexible, and its chemical building blocks offer fewer distinct recognition features than proteins typically do. Those properties can make it difficult to design a molecule that binds one RNA selectively rather than interacting with other RNAs or cellular components.
#1 Best Overall
There can still be more tractable recognition sites. Stable RNA folds and particular structural elements may provide features a ligand can recognize. The challenge is to find a ligand that binds the intended structure and retains selectivity and useful activity in cells.
What later work says about possible approaches
A 2022 review of RNA-binding macrocyclic peptides describes three broad ways researchers have pursued such ligands. This is field context, not evidence that the 2014 Chemistry World item used any of these methods.
| Discovery approach | Basic idea |
|---|---|
| Mimic RNA-binding proteins | Use protein-inspired features to guide the design of molecules that recognize RNA. |
| Screen peptide libraries | Test collections of peptides to identify candidates that bind RNA. |
| Adapt natural products | Use natural-product molecules as starting points for RNA-binding ligand discovery. |
The review discusses macrocyclic peptides, one ligand class among several possible ways to target RNA. Its scope does not establish that the 2014 headline was about peptides, or that its reported synthetic strategy belongs to any of these three categories. See the 2022 review of RNA-binding macrocyclic peptides.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsWhy binding alone does not make a therapy
A molecule that binds RNA in a biochemical experiment is not automatically a useful drug. The review identifies selectivity, cell permeability, and distribution inside cells as important obstacles, along with the challenge of translating laboratory findings into animal models.
For the RNA-binding molecules covered by that review, animal experiments and clinical trials had not been reported at the time, apart from some ribosome-targeting antibiotic peptides. That statement applies to the review’s described examples; it should not be generalized to every RNA-targeting program or read as an update on all work since publication. The review notes that ribosome-targeting antibiotics are an exception, not proof that other RNA-binding candidates are clinically ready.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How to interpret “undruggable”
In this headline, “undruggable” is best read as shorthand for a difficult drug-discovery target class, not as a literal claim that small RNAs are impossible to target. A useful assessment of any proposed RNA-targeting approach would ask:
Rank #4
- Used Book in Good Condition
- Which RNA and structural feature does the molecule target?
- What ligand type and discovery method were used?
- Was selective binding demonstrated against relevant alternatives?
- Did the molecule act in cells, and was delivery or intracellular distribution addressed?
- What evidence exists in animals or people?
For the 2014 report, the archive summary alone does not answer those questions. Without the original article or its primary study, its target, method, and experimental results remain unverified.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
